Quick answer
Regenerative biologics describes a category of consultation-based wellness options that include Ultracell, Exosomes, RPA, Muse Exosomes, Cord Blood, MSC, and Muse. Selection is physician-guided after intake, labs, and provider review.
The vocabulary, kept simple
Terminology in this space is dense and changes frequently. Here are the terms most commonly referenced during consultations, framed plainly.
- Ultracell — a branded regenerative option discussed during private consultation.
- Exosomes — small extracellular vesicles studied in regenerative contexts.
- RPA — referenced in some consultation menus; selection is provider-led.
- Muse Exosomes — a specific exosome variant referenced in select protocols.
- Cord Blood — sourced from umbilical cord blood; selection is consultation-based.
- MSC — mesenchymal stem cells, a category frequently referenced in regenerative consultations.
- Muse — a specific cell type referenced in select protocols.
How selection actually works
No reputable provider chooses a biologic sight unseen. Selection follows intake, labs, history, and goals. Suitability is confirmed during consultation, and not every individual is a candidate.
Setting honest expectations
Our regenerative biologics program is wellness-focused and consultation-based. It is not a cure, not a guarantee, and not a substitute for disease-specific medical care. Results vary, and your provider will explain what is reasonable to expect.
Frequently asked
- Is this a disease treatment?
- No. Our regenerative biologics program is wellness-focused. It is not a substitute for diagnosis or disease-specific treatment.
- Which option is right for me?
- Selection is physician-guided after intake, labs, and provider review. There is no universal answer.
- Are results guaranteed?
- No. Results vary by individual, protocol, and goals. We do not make outcome guarantees.
Related services
Ready to talk with our team?
Book a complimentary consultation at our Rancho Palos Verdes or West Palm Beach clinic.
Request a ConsultationRelated reading
More from the EBO2 Therapy and Wellness library.
How Physician-Guided Longevity Care Works
Learn how physician guided longevity care works, from private screening and targeted testing to personalized, provider-guided wellness protocols today.
Read
How EBO2 Therapy Sessions Work in Practice
Learn how ebo2 therapy sessions work with private screening, monitored care, recovery guidance, and personalized planning at concierge wellness clinics.
ReadIV Therapy: A Personalized Wellness Approach
Explore physician-supervised IV therapy, from personalized nutrient selection and screening to recovery, cellular wellness, and concierge care planning.
ReadFDA approvals for cellular products are narrow and product-specific: RYONCIL is approved only for pediatric steroid-refractory acute GVHD, and ALLOCORD is approved only for hematopoietic reconstitution in specific disorders. These narrow approvals do NOT validate other MSC, cord-blood, exosome, injection, orthopedic, anti-aging, or wellness uses. There are no FDA-approved exosome products, and published human trials of MSC, exosome, and related regenerative products remain heterogeneous and early-phase.
- RYONCIL (remestemcel-L) — FDA prescribing label
DailyMed (U.S. National Library of Medicine)
FDA-approved prescribing information for RYONCIL — the first FDA-approved allogeneic MSC product, limited to pediatric steroid-refractory acute GVHD. Approval does not extend to other MSC uses.
- ALLOCORD (HPC, cord blood) — FDA prescribing label
DailyMed (U.S. National Library of Medicine)
FDA-approved prescribing information for ALLOCORD, limited to hematopoietic reconstitution in specific inherited or acquired disorders. Approval does not extend to regenerative, orthopedic, or wellness cord-blood uses.
- FDA consumer alert on regenerative medicine products including stem cells and exosomes
U.S. Food & Drug Administration
FDA public alert stating there are no FDA-approved exosome products and describing the limits of FDA-approved regenerative products.
- FDA — Important Patient and Consumer Information About Regenerative Medicine Therapies
U.S. Food & Drug Administration
Consumer-facing FDA guidance on how to evaluate marketed regenerative medicine claims and providers.
- Systematic review of mesenchymal stem cell and cell-derived product trials (PMID 38958077)
Peer-reviewed systematic review (PMID 38958077)
Systematic review describing heterogeneous, early-phase human trials of MSC and cell-derived regenerative products; overall clinical evidence remains inconclusive.
References describe general evidence, safety, or regulatory context. They do not establish an individual benefit for any specific person, and they do not validate EBO2's proprietary clinic protocols.
Medical Disclaimer: This article is educational and is not a substitute for medical advice, diagnosis, or treatment. Programs are physician-guided, consultation-based, and personalized after screening. Results vary.
